3/5
08:11 am
iobt
IO Biotech, Inc. (NASDAQ: IOBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Neutral
Report
IO Biotech, Inc. (NASDAQ: IOBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
3/4
04:17 pm
iobt
IO Biotech Reports 2024 Business Highlights
Low
Report
IO Biotech Reports 2024 Business Highlights
2/23
12:10 pm
iobt
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference [Yahoo! Finance]
Medium
Report
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference [Yahoo! Finance]
2/23
12:07 pm
iobt
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
Medium
Report
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
2/21
02:14 am
iobt
IO Biotech to Present at the 45th Annual Cowen Health Care Conference [Yahoo! Finance]
Low
Report
IO Biotech to Present at the 45th Annual Cowen Health Care Conference [Yahoo! Finance]
2/20
08:05 am
iobt
IO Biotech to Present at the 45th Annual Cowen Health Care Conference
High
Report
IO Biotech to Present at the 45th Annual Cowen Health Care Conference
2/17
01:06 pm
iobt
Cancer Vaccines Market on Track for Major Expansion in the 7MM Amid Immunotherapy Advancements, Predicts DelveInsight [Yahoo! Finance]
Medium
Report
Cancer Vaccines Market on Track for Major Expansion in the 7MM Amid Immunotherapy Advancements, Predicts DelveInsight [Yahoo! Finance]
2/4
08:50 am
iobt
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate [Yahoo! Finance]
Medium
Report
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate [Yahoo! Finance]
2/4
08:05 am
iobt
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate
Medium
Report
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate
1/9
08:05 am
iobt
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
Low
Report
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
12/20
08:09 am
iobt
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank [Yahoo! Finance]
Low
Report
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank [Yahoo! Finance]
12/20
08:05 am
iobt
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank
Low
Report
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank